Description

Simple

Clinical

Overview

Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Gevokizumab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Gevokizumab.
Abituzumab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Gevokizumab.
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Gevokizumab.
Aducanumab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Gevokizumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gevokizumab.
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Gevokizumab.
Amatuximab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Gevokizumab.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Gevokizumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Gevokizumab.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Gevokizumab.
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gevokizumab.
Apolizumab
The risk or severity of adverse effects can be increased when Apolizumab is combined with Gevokizumab.
Apomab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Ascrinvacumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Gevokizumab.